← All trials
NCT02232425
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2014
- Primary completion
- Oct 1, 2015
- Completion date
- Oct 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 88
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Ixchelsis LimitedLead sponsor
- New England Research InstitutesCollaborator
- Ixchelsis LimitedStudy director
- PHT CorporationCollaborator
- NovotechCollaborator
- ICONCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.